Today: 18 November 2025
Subscribe
Browse Category

Mergers & Acquisitions News 3 October 2025 - 11 October 2025

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Overview of Strive and Its Role: Strive Asset Management began as an ETF issuer and anti-ESG investment firm (co-founded by Ramaswamy in 2022) etf.com globenewswire.com. In 2025 it transformed into a dedicated Bitcoin-treasury company. Strive’s business is to raise capital (through equity/debt) and convert it into Bitcoin holdings. The company uses a “preferred equity only” leverage model (no debt) to accumulate crypto globenewswire.com. By merger and acquisitions, Strive aims to become a large public company that simply hoards Bitcoin. Its own COO calls this building a “scaled, innovative and accretive Bitcoin acquisition platform” globenewswire.com. In practice, Strive is effectively a
11 October 2025
 ·  ·  ·  · 
Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Protagonist Therapeutics: Small Biotech Skyrockets on Buyout Buzz & Breakthrough Trials

Company Overview Protagonist Therapeutics is a clinical-stage biopharma company leveraging peptide technology to create new medicines for rare hematologic conditions and prevalent immunological diseases protagonist-inc.com. Founded in 2008, Protagonist has built its identity around engineered peptide drugs – a niche between small molecules and antibodies – to tackle challenging targets with oral or injectable therapies. The company’s mission centers on “developing groundbreaking new medicines to treat both rare and prevalent diseases” using its proprietary peptide platform protagonist-inc.com. This focus has led to a pipeline addressing blood cancers/disorders and inflammatory bowel and skin diseases, where current treatments are inadequate. Leadership &
11 October 2025
 ·  ·  ·  · 
Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Protagonist Therapeutics (PTGX) Skyrockets on J&J Buyout Buzz Amid Clinical Breakthroughs

Recent News and Corporate Developments J&J Buyout Buzz: The biggest news propelling Protagonist’s stock is the report that Johnson & Johnson is in talks to acquire Protagonist reuters.com. On October 10, 2025, The Wall Street Journal broke the story (later confirmed by Reuters) that J&J is negotiating a purchase of Protagonist Therapeutics reuters.com. This potential acquisition would build on the companies’ ongoing partnership: J&J’s Janssen unit has held exclusive worldwide rights to develop and commercialize Protagonist’s peptide drug Icotrokinra (JNJ-2113) since a 2017 collaboration deal reuters.com. In fact, J&J already holds rights to market Icotrokinra and reportedly owns a ~4% stake in Protagonist, reflecting its early
10 October 2025
 ·  ·  ·  ·  · 
Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

Bristol Myers Snaps Up Orbital Therapeutics in $1.5B Biotech Power Play

In-Depth Analysis BMS’s acquisition of Orbital Therapeutics marks a deliberate push into autoimmune disease treatment via advanced cell therapy. Orbital, founded in 2022 by leaders in RNA and immunology, has built a proprietary RNA platform combining circular and linear RNA engineering with sophisticated lipid nanoparticle (LNP) delivery news.bms.com fiercebiotech.com. Its lead program, OTX-201, is designed as an in vivo CAR‑T: instead of harvesting and engineering cells outside the body, Orbital will inject circular RNA encoding a CD19-directed CAR into the patient, so the patient’s own T cells become the “manufacturers” of CAR‑T cells in situ news.bms.com orbitaltx.com. This approach could
10 October 2025
 ·  ·  ·  ·  · 
MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

MEDIROM (NASDAQ: MRM) Set for Takeoff: Series A Boost & Altman-Backed ‘Orb’ Deal Fuels 150% Upside

Company Background & Business Model MEDIROM Healthcare Technologies (NASDAQ: MRM) is a Tokyo‑based provider of holistic health and wellness services. Founded in 2000, it operates 300+ Re.Ra.Ku branded relaxation salons across Japan medirom.co.jp, offering massage, aromatherapy and lifestyle therapy. These salons generate the bulk of revenues (47.3M of $52.7M in 2024) ir.medirom.co.jp. In parallel, since 2015 MEDIROM has built a Digital Preventative Healthcare arm. Key elements are: the Lav® on-demand health‐guidance app, and the MOTHER Bracelet®, a battery‑free wearable activity tracker. In 2023 it launched REMONY, a remote health monitoring service bundling the MOTHER Bracelet with corporate wellness programs medirom.co.jp.
9 October 2025
 ·  ·  ·  ·  · 
Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Akero Therapeutics (AKRO) Skyrockets on $5.2 B Novo Nordisk Buyout – Pipeline Breakthroughs & Expert Outlook

Sources: Akero Therapeutics investor materials; Novo Nordisk press statements; Reuters, TS2.tech and FierceBiotechnews reports ts2.tech ts2.tech fiercebiotech.com; MarketBeat and DirectorsTalk analyst surveys marketbeat.com directorstalkinterviews.com; Economic Times deal summary economictimes.indiatimes.com economictimes.indiatimes.com; Business Wire legal alert businesswire.com businesswire.com; and TradingView market data marketbeat.com tradingview.com.
9 October 2025
 ·  ·  ·  ·  ·  · 
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent (CFLT) Stock Surges on Takeover Rumors – What’s Next for the Data Streaming Pioneer?

Latest News and Developments Confluent’s headquarters in Silicon Valley. The company’s rumored sale exploration has made headlines, spurring a surge in its stock price as investors speculate on a potential acquisition. The biggest recent news for Confluent came on October 8, 2025, when a Reuters exclusive reported that the company is exploring a sale after receiving takeover interest reuters.com. According to the report, multiple private equity firms and tech companies approached Confluent, prompting it to work with an investment bank on a possible deal reuters.com. This development reflects how valuable real-time data streaming has become in the age of AI – Confluent’s technology is seen
8 October 2025
 ·  ·  ·  ·  · 
Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Confluent, Inc. (CFLT) – Will a Real‑Time Data Pioneer Become a Takeover Target? (October 8 2025)

Stock Price & Short‑Term Performance Confluent trades on the NASDAQ under ticker CFLT. According to the company’s historical price lookup, the stock closed at $21.26 on 6 Oct 2025 and dropped to $20.73 on 7 Oct investors.confluent.io. Technical analysis from StockInvest.us notes the stock fell 2.49 % on 7 Oct, trading between $20.12 and $21.33, and it has declined in six of the last ten sessions stockinvest.us. Volume was ~7 M shares, lower than earlier sessions, suggesting reduced risk stockinvest.us. The near‑term outlook is cautious: the share price is in a falling short‑term trend with predicted downside of almost 19 % if the trend persists. However, both
8 October 2025
 ·  ·  ·  ·  · 
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Fifth Third’s $10.9 B Comerica Takeover Shakes Up Banking – Will Comerica Park Get a New Name?

A $10.9 B Deal to Create a Top-10 Bank Fifth Third Bancorp, based in Cincinnati, agreed to acquire Comerica Inc. of Dallas in an all-stock transaction valued at $10.9 billion reuters.com. The merger will form the nation’s ninth-largest bank by assets, a financial giant with approximately $288 billion in total assets and a deep footprint across multiple regions reuters.com ts2.tech. Under the deal terms announced October 6, each Comerica share will be exchanged for 1.8663 shares of Fifth Third stock ir.53.com. At Fifth Third’s pre-announcement share price, that equates to $82.88 per Comerica share, representing about a 20% premium over Comerica’s recent average
6 October 2025
 ·  ·  ·  ·  ·  · 
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Current Stock Performance & Market Reaction The announcement of Fifth Third Bancorp’s planned acquisition of Comerica sent CMA stock soaring. On 6 October 2025, Comerica’s investor‑relations website showed the stock opening near $81.00 and trading around $79.62–$80.56, up 9–14 % from the previous close investor.comerica.com. MarketWatch reported that CMA shares rallied 15.1 % to $81.20, a three‑year high, while Fifth Third’s shares dipped 0.3 % morningstar.com. The initial spike reflected the generous 20 % premium offered by Fifth Third and expectations that the combined bank would command more market share. Investors also reacted to a brighter regulatory outlook. Reuters noted that U.S. regulators have streamlined bank‑merger
6 October 2025
 ·  ·  ·  ·  ·  · 
White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

White Mountains Stock Rockets +10% on $1.75B Bamboo Deal – What Investors Need to Know

Figure: White Mountains’ share price spiked on Oct. 3, 2025 after announcing the $1.75B Bamboo sale reuters.com investing.com. Stock Surge on Oct. 3, 2025 White Mountains saw one of its biggest single-day moves in years on Oct. 3, 2025. After closing the prior day near $1,665, WTM stock jumped nearly 11% intraday reuters.com, settling around $1,841 by market close (a gain of +10.62% from the previous close). This surge was driven by the surprise announcement that morning: WTM signed an agreement to sell most of its Bamboo homeowners insurance business to private equity firm CVC reuters.com investing.com. Investors reacted strongly because Bamboo had been
3 October 2025
 ·  ·  ·  ·  · 
White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

White Mountains Stock Skyrockets on $1.75B Bamboo Deal and Major CEO Shake-Up

Stock Performance & Market Data Price: As of Oct 3, 2025 (morning), WTM is trading around $1,820 per share markets.financialcontent.com. It opened near $1,785 and hit intraday highs ~$1,863 markets.financialcontent.com. This is significantly above the prior close of $1,664.56 on Oct 2 markets.financialcontent.com. The stock’s 52-week range is roughly $1,648–$2,023 investing.com. Daily Move: The Oct 3 rally (up ≈9.3%) was driven by the Bamboo sale announcement. YTD: For 2025, WTM is down about 5.7% markets.financialcontent.com. Over the past week, the stock had been near its 52-week low (~$1,650) before rebounding on Oct 3. Volume: The price jump was on moderate
3 October 2025
 ·  ·  ·  ·  ·  · 
1 … 8 9 10 11 12
Go toTop